EUVIMEDEUVIMED entdecken
Crossref

Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer

Deborah Di-Xin Zhou iD, Janene Dalrymple iD, Danielle Klingberg, Frank Po-Yen Lin iD, Sarah J Lord, Wendy A Cooper iD, Milita Zaheed iD, Robert John Simes iD, Thomas John iD, Chee Khoon Lee

JCO Precision Oncology · 2025

DOI: 10.1200/po-24-00673 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2025. Verfasst von Deborah Di-Xin Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Oncogenes, Genes, Tumor Suppressor. Die Arbeit nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Next-generation sequencing in non–small cell lung cancer (NSCLC) identifies somatic genomic variants (SGVs) in cancer susceptibility genes (CSGs). We hypothesized that SGVs would be associated with poorer overall survival (OS) but greater benefit with immune checkpoint inhibitors over chemotherapy. We investigated the prevalence and predictive value of SGVs, using data from OAK and POPLAR trials comparing atezolizumab with docetaxel. METHODS We curated a list of SGVs (excluding TP53 , EGFR , ALK , and ROS1 ) on the basis of CSGs associated with tumorigenesis. We classified participants as SGV mutant or wild-type using baseline plasma analyzed by the FoundationOne Liquid CDx assay. Cox regression analyses and interaction tests between SGV status and treatment were performed. RESULTS Of 762 participants, 29% harbored an SGV. The SGV mutant group had worse OS (hazard ratio [HR], 1.28, 95% CI, 1.06 to 1.54), and within each treatment arm (docetaxel: HR, 1.31; atezolizumab: HR, 1.27). In the atezolizumab arm, the SGV mutant group compared with wild-type had worse OS in the PD-L1 high (HR, 1.31 [95% CI, 0.59 to 2.91]) and low (HR, 1.38 [95% CI, 0.98 to 1.93]) subgroups. SGV with missense, splice, and nonsense mutations had significantly worse OS than wild-type in the docetaxel arm (log-rank P = .01) but not in the atezolizumab arm (log-rank P = .33). SGV status did not predict greater OS benefit with atezolizumab over docetaxel (interaction P = .67). CONCLUSION In advanced NSCLC after chemotherapy progression, plasma-detected SGVs are common, and associated with inferior OS. Plasma SGV status should be considered as a stratification factor in future trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsOncogenesGenes, Tumor SuppressorHumansDocetaxelMaleFemaleMiddle AgedAgedAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitors

Substanzen

DocetaxelatezolizumabAntibodies, Monoclonal, HumanizedImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • NHMRC Clinical Trials Centre, University of Sydney, Camperdown, NSW, Australia.
  • St George Hospital, Kogarah, NSW, Australia.
  • Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, NSW Health Pathology, Camperdown, NSW, Australia.
  • Faculty of Medicine and Health and Western Sydney University School of Medicine, University of Sydney, Camperdown, NSW, Australia.
  • Prince of Wales Hereditary Cancer Centre, Randwick, NSW, Australia.
  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.

ORCID-Profile: Deborah Di-Xin Zhou, Janene Dalrymple, Frank Po-Yen Lin, Wendy A Cooper, Milita Zaheed, Robert John Simes, Thomas John

Zitieren

APA

Zhou, D. D., Dalrymple, J., Klingberg, D., Lin, F. P., Lord, S. J., Cooper, W. A., Zaheed, M., Simes, R. J., John, T., & Lee, C. K. (2025). Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. https://doi.org/10.1200/po-24-00673

Vancouver

Zhou DD, Dalrymple J, Klingberg D, Lin FP, Lord SJ, Cooper WA, et al. Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer. JCO Precision Oncology. 2025. doi:10.1200/po-24-00673

BibTeX
@article{Zhou2025,
  author = {Zhou, Deborah Di-Xin and Dalrymple, Janene and Klingberg, Danielle and Lin, Frank Po-Yen and Lord, Sarah J and Cooper, Wendy A and Zaheed, Milita and Simes, Robert John and John, Thomas and Lee, Chee Khoon},
  title = {Clinical Impact of Somatic Genomic Variants of Oncogenes and Tumor Suppressor Genes in Previously Treated Advanced Non–Small Cell Lung Cancer},
  journal = {JCO Precision Oncology},
  year = {2025},
  doi = {10.1200/po-24-00673}
}
Kostenlos starten →